RESUMEN
Background: Although the inferior petrosal sinus (IPS) is the most common approach route for transvenous embolization (TVE) of cavernous sinus dural arteriovenous fistulas (CSDAVFs), other routes should be chosen in cases which the IPS is occluded. We report a case in which the superior ophthalmic vein (SOV) approach through the facial vein (FV) was the first choice to achieve radical cure of a hemorrhage-onset CSDAVF. Case Description: An 81-year-old female presented with a history of transarterial embolization (TAE) and TVE for the left CSDAVF 27 years ago. She was transported to us with a chief complaint of consciousness disturbance, and head computed tomography (CT) showed subcortical hemorrhage in the right frontal lobe. Cerebral angiography revealed CSDAVF with draining into the right SOV and right superficial middle cerebral vein (SMCV). Angiography, computed tomography venography, and contrast-enhanced magnetic resonance imaging did not show IPS, but the outflow pathways to the SOV, FV, and internal jugular vein were confirmed, so an approach through the FV was selected. Conclusion: The FV was selected through the right femoral vein and thanks to the distal access catheter (DAC) being guided to the SOV, the microcatheter could be easily guided to the SMCV through the cavernous sinus (CS). TVE was performed, complete occlusion was confirmed. When preoperative occlusion of the IPS was confirmed, the FV was useful for the first choice of route, and the use of DAC allowed us to complete the treatment accurately and quickly.
RESUMEN
Carnitine palmitoyltransferase II (CPT II) deficiency is a rare inherited disorder related to recurrent episodes of rhabdomyolysis. The adult myopathic form of CPT II deficiency is relatively benign and difficult to diagnose. The point mutation S113L in CPT2 is very common in Caucasian patients, whereas F383Y is the most common mutation among Japanese patients. We herein present a case of CPT II deficiency in a Japanese patient homozygous for the missense mutation S113L. The patient showed a decreased frequency of rhabdomyolysis recurrence after the administration of a diet containing medium-chain triglyceride oil and supplementation with carnitine and bezafibrate.
Asunto(s)
Bezafibrato/uso terapéutico , Carnitina O-Palmitoiltransferasa/deficiencia , Carnitina/uso terapéutico , Suplementos Dietéticos , Errores Innatos del Metabolismo Lipídico/dietoterapia , Errores Innatos del Metabolismo/dietoterapia , Rabdomiólisis/diagnóstico , Pueblo Asiatico , Bezafibrato/sangre , Carnitina/sangre , Carnitina O-Palmitoiltransferasa/sangre , Carnitina O-Palmitoiltransferasa/genética , Homocigoto , Humanos , Errores Innatos del Metabolismo Lipídico/sangre , Errores Innatos del Metabolismo Lipídico/genética , Masculino , Errores Innatos del Metabolismo/sangre , Errores Innatos del Metabolismo/genética , Persona de Mediana Edad , Mutación Puntual , Rabdomiólisis/dietoterapia , Rabdomiólisis/genética , Resultado del TratamientoRESUMEN
Quantitative proteome analysis of Alzheimer's disease (AD) brains was performed using two-dimensional (2-D) gels in order to find out the pathological protein expression in AD. We sequentially extracted brain proteins using two distinct sample solutions, yielding different protein fractions (fraction A and B). These fractions showed distinct 2-DE patterns with high resolution and excellent reproducibility. In fraction A (solubilized by urea and Nonidet P-40 (NP-40)), approximately 1300 protein spots were detected, and the relative volume (%VOL) significantly increased in five spots and significantly decreased in 10 spots in AD. The proteins identified include enzymes, molecular chaperones and cytoskeletal proteins. In fraction B (solubilized by urea, thiourea, N-decyl-N,N-dimethyl-3-ammonio-1-propane sulfonate (SB3-10) and 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS)), over 500 protein spots were detected in the 2-DE data analysis. The %VOL of three spots was significantly increased in AD. Two of these spots were identified as glial fibrillary acidic protein (GFAP) using mass spectrometry. These results suggest that subproteomics following sequentially extracted brain proteins is a useful method for the analysis of brain extracts containing hydrophobic proteins. Our findings will prompt further study on disease-linked proteins for the investigation of AD pathogenesis and the quest for disease markers.
Asunto(s)
Enfermedad de Alzheimer/metabolismo , Encéfalo/metabolismo , Tejido Nervioso/metabolismo , Proteínas/metabolismo , Proteoma/metabolismo , Anciano , Enfermedad de Alzheimer/patología , Encéfalo/patología , Electroforesis en Gel Bidimensional/métodos , Proteína Ácida Fibrilar de la Glía/metabolismo , Humanos , Espectrometría de Masas/métodos , Proteínas de la Membrana , Persona de Mediana Edad , Tejido Nervioso/patología , Valores de ReferenciaRESUMEN
Parkinson's disease (PD) is one of the most prevalent neurodegenerative diseases but its etiology is unclear. Alpha-synuclein (alpha-SN) is a major component of Lewy bodies and Lewy neurites, and its missense mutations, A30P and A53T, cause familial PD. In PD, alpha-SN-positive glial inclusions are distributed mainly in the dorso-medial region of the substantia nigra, which contains most of the surviving dopaminergic neurons, suggesting that alpha-SN expression might have a neuroprotective function in glial cells. To investigate this hypothesis, we established alpha-SN transfected C6 glioma cell line clones and evaluated the expression of neurotrophins using semi-quantitative reverse transcription polymerase chain reaction and enzyme-linked immunosorbent assay. Brain-derived neurotrophic factor (BDNF) was induced by overexpression of wild-type alpha-SN but not by that of A30P and A53T. These data suggest that the pathogenic alpha-SN mutations, A30P or A53T, are linked to the loss of BDNF production in glial cells.
Asunto(s)
Factor Neurotrófico Derivado del Encéfalo/biosíntesis , Ácido Egtácico/análogos & derivados , Glioma/metabolismo , Proteínas del Tejido Nervioso/fisiología , Sustitución de Aminoácidos , Animales , Factor Neurotrófico Derivado del Encéfalo/antagonistas & inhibidores , Calcio/química , Calcio/metabolismo , Línea Celular Tumoral , Quelantes/farmacología , Células Clonales , Dactinomicina/farmacología , Ácido Egtácico/farmacología , Humanos , Immunoblotting , Inmunohistoquímica , Operón Lac , Factor de Crecimiento Nervioso/biosíntesis , Proteínas del Tejido Nervioso/genética , Proteínas del Tejido Nervioso/metabolismo , Inhibidores de la Síntesis de la Proteína/farmacología , ARN Mensajero/biosíntesis , Ratas , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Sinucleínas , Tapsigargina/farmacología , Transfección , alfa-SinucleínaRESUMEN
Parkinson's disease is characterized by dopaminergic neuronal death and the presence of Lewy bodies. alpha-Synuclein is a major component of Lewy bodies, but the process of its accumulation and its relationship to dopaminergic neuronal death has not been resolved. Although the pathogenesis has not been clarified, mitochondrial complex I is suppressed, and caspase-3 is activated in the affected midbrain. Here we report that a combination of 1-methyl-4-phenylpyridinium ion (MPP(+)) or rotenone and proteasome inhibition causes the appearance of alpha-synuclein-positive inclusion bodies. Unexpectedly, however, proteasome inhibition blocked MPP(+)- or rotenone-induced dopaminergic neuronal death. MPP(+) elevated proteasome activity, dephosphorylated mitogen-activating protein kinase (MAPK), and activated caspase-3. Proteasome inhibition reversed the MAPK dephosphorylation and blocked caspase-3 activation; the neuroprotection was blocked by a p42 and p44 MAPK kinase inhibitor. Thus, the proteasome plays an important role in both inclusion body formation and dopaminergic neuronal death but these processes form opposite sides on the proteasome regulation in this model.
Asunto(s)
Acetilcisteína/análogos & derivados , Cisteína Endopeptidasas/fisiología , Dopaminérgicos/metabolismo , Dopamina/metabolismo , Complejos Multienzimáticos/antagonistas & inhibidores , Complejos Multienzimáticos/fisiología , Proteínas del Tejido Nervioso/metabolismo , Neuronas/metabolismo , 1-Metil-4-fenilpiridinio/farmacología , Acetilcisteína/farmacología , Animales , Encéfalo/metabolismo , Caspasa 3 , Inhibidores de Caspasas , Caspasas/metabolismo , Cisteína Endopeptidasas/metabolismo , Relación Dosis-Respuesta a Droga , Inhibidores Enzimáticos/farmacología , Herbicidas/farmacología , Immunoblotting , Inmunohistoquímica , Iones , L-Lactato Deshidrogenasa/metabolismo , Leupeptinas/farmacología , Sistema de Señalización de MAP Quinasas , Masculino , Mitocondrias/metabolismo , Proteína Quinasa 1 Activada por Mitógenos/metabolismo , Proteína Quinasa 3 Activada por Mitógenos , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Complejos Multienzimáticos/metabolismo , Neuronas/patología , Fosforilación , Complejo de la Endopetidasa Proteasomal , Ratas , Ratas Wistar , Rotenona/metabolismo , Rotenona/farmacología , Sinucleínas , Factores de Tiempo , Ubiquitina/metabolismo , alfa-SinucleínaRESUMEN
One pathological characteristic of Alzheimer's disease (AD) is extensive synapse loss. Presenilin 1 (PS1) is linked to the pathogenesis of early onset familial Alzheimer's disease (FAD) and is localized at the synapse, where it binds N-cadherin and modulates its adhesive activity. To elucidate the role of the PS1/N-cadherin interaction in synaptic contact, we established SH-SY5Y cells stably expressing wild-type (wt) PS1 and dominant-negative (D385A) PS1. We show that the formation of cadherin-based cell-cell contact among SH-SY5Y cells stably expressing D385A PS1 was suppressed. Conversely, wt PS1 cells exhibited enhanced cell-cell contact and colony formation. Suppression of cell-cell contact in D385A cells was accompanied by an alteration in N-cadherin subcellular localization; N-cadherin was retained mainly in the endoplasmic reticulum (ER) and cell surface expression was reduced. We conclude that PS1 is essential for efficient trafficking of N-cadherin from the ER to the plasma membrane. PS1-mediated delivery of N-cadherin to the plasma membrane is important for N-cadherin to exert its physiological function, and it may control the state of cell-cell contact.
Asunto(s)
Enfermedad de Alzheimer/metabolismo , Cadherinas/metabolismo , Adhesión Celular/genética , Membrana Celular/metabolismo , Proteínas de la Membrana/deficiencia , Terminales Presinápticos/metabolismo , Enfermedad de Alzheimer/genética , Enfermedad de Alzheimer/fisiopatología , Encéfalo/metabolismo , Encéfalo/fisiopatología , Agregación Celular/genética , Comunicación Celular/genética , Línea Celular , Membrana Celular/genética , Proteínas del Citoesqueleto/metabolismo , Retículo Endoplásmico/metabolismo , Humanos , Sustancias Macromoleculares , Proteínas de la Membrana/genética , Peso Molecular , Mutación/genética , Presenilina-1 , Terminales Presinápticos/patología , Unión Proteica/genética , Transporte de Proteínas/genética , Membranas Sinápticas/genética , Membranas Sinápticas/metabolismo , Transactivadores/metabolismo , beta CateninaRESUMEN
Presenilin 1 interacts with beta-catenin, an essential component of the Wnt signaling pathway. To elucidate the role of presenilin 1-beta-catenin interaction in neuronal differentiation, we established SH-SY5Y cells stably expressing wild-type presenilin 1, P117L mutant presenilin 1, which is linked to the early-onset familial form of Alzheimer's disease, and D385A mutant presenilin 1, which has no aspartyl proteinase activity. We demonstrate that SH-SY5Y cells stably expressing D385A mutant presenilin 1 failed to differentiate in response to retinoic acid treatment. Retinoic acid caused an increase in nuclear beta-catenin levels in SH-SY5Y cells, which was followed by an increase in cyclin D1 protein levels. Abnormal cellular accumulation of beta-catenin was observed in D385A mutant transfected cells, whereas nuclear beta-catenin and cellular cyclin D1 levels failed to increase. Conversely, SH-SY5Y cells expressing the P117L mutant differentiated normally and showed increased nuclear beta-catenin and cellular cyclin D1 levels. These findings suggest that neuronal differentiation of SH-SY5Y cells involves the Wnt signaling pathway and that presenilin 1 plays a crucial role in Wnt signal transduction by regulating the nuclear translocation of beta-catenin.
Asunto(s)
Proteínas de la Membrana/biosíntesis , Proteínas Proto-Oncogénicas/biosíntesis , Transducción de Señal/efectos de los fármacos , Tretinoina/farmacología , Proteínas de Pez Cebra , Diferenciación Celular/efectos de los fármacos , Diferenciación Celular/fisiología , Humanos , Proteínas de la Membrana/genética , Mutación/efectos de los fármacos , Mutación/fisiología , Presenilina-1 , Proteínas Proto-Oncogénicas/genética , Transducción de Señal/fisiología , Transfección/métodos , Células Tumorales Cultivadas/citología , Células Tumorales Cultivadas/efectos de los fármacos , Células Tumorales Cultivadas/metabolismo , Proteínas WntRESUMEN
Many cases of autosomal dominant early onset familial Alzheimer's disease result from mutations in presenilin-1 (PS1). In this study, we examined the role of the PS1 homologue gene sel-12 of Caenorhabditis elegans under oxidative stress and clarified the sel-12-induced apoptosis. A genetic null allele mutant, sel-12(ar171), showed resistance to oxidative stress and prevented mitochondrial dysfunction-induced apoptosis. On the other hand, another allele mutant, sel-12(ar131), that carries a missense mutation showed a proapoptotic activity, which may be the result of a gain of function property. Also, sel-12(ar131)-induced apoptosis was ced-3- and ced-4-dependent. Dantrolene, which specifically inhibits Ca(2+) release from endoplasmic reticulum stores, prevents sel-12(ar131)-induced apoptosis. SEL-12, which is localized in the endoplasmic reticulum, may induce apoptosis through abnormal calcium release from the endoplasmic reticulum. Together, with the previous finding that human PS1 could substitute for SEL-12, these results suggest the similar involvement of PS1-inducing apoptosis under oxidative stress and mitochondrial dysfunction in the Alzheimer's Disease brain.